FBP1 and neoplasm: Other preclinical evidence suggests that FBP1 overexpression acts as a tumor suppressor [37]; however, the lack of tumorigenesis with salicylate suggests that allosteric inhibition is a way of inhibiting FBP1, without promoting tumor progression.